Unlock stock picks and a broker-level newsfeed that powers Wall Street.

CDW Holding updates on diversification efforts and sustainability direction

In This Article:

CDW Holding Limited
CDW Holding Limited
  • As part of its diversification efforts, the Group has been pursuing new business opportunities which are aimed at transforming traditional industries to be more environment-friendly and to improve human life

  • The diversification businesses span diverse industries like drug development, skincare, clean energy, and water purification

  • Adopts UN Sustainable Development Goals as a framework to guide diversification efforts

SINGAPORE, May 24, 2022 (GLOBE NEWSWIRE) -- SGX Mainboard-listed CDW Holding Limited (“CDW”, the “Company”, or collectively with its subsidiaries, the “Group”) is pleased to share an update on its diversification efforts and announce a new strategic direction for the Group, centred around the United Nations’ Sustainable Development Goals (“UN SDGs”).

CDW’s Diversification Efforts
The Group is a leading manufacturer of LCD Backlight Units for applications in various industries such as computer, automotive, and gaming and has recently also built up a promising OEM business in producing electronic payments systems and digital content editing devices. As the Group operates in a challenging industry with intense price competition and shortening product life cycles, it embarked on a diversification strategy in 2016 to identify other potential areas of growth and made its foray into Bio & life sciences and other businesses.

Bio & Life Sciences
The Group holds a patent for a synthetic antibody library through its subsidiary GSP Enterprise Inc. (“GSP”), which was established by the late Honorary Professor Shimizu Nobuyoshi of Keio University and acquired by the Company in 2018. GSP builds upon the late Professor Shimizu Nobuyoshi’s fundamental research in the medical field through developing specific antibodies to target tumours, viruses or other diseases, with the aim of creating immunotherapies for them. A Biotech Co., Ltd (“ABio”) was established in South Korea at the same time for antibody-related research and development.

The Group had previously announced key milestones in the development of novel antibody drugs aimed at treating various cancers. The most promising candidate thus far, the anti-Cripto-1 antibody, was patented in September 2020 and has been shown to be effective at inhibiting the self-proliferation of cancer stem cells. Recent anti-Cripto-1 antibody research have been led by ABio, which is conducting a pre-clinical efficacy study at the National Cancer Centre of Korea.

The late Professor Emeritus Nobuyoshi Shimizu of Keio University passed away from cancer in 2015 after founding GSP to commercialize his research. In 2018, we acquired GSP to continue the late Professor Shimizu's legacy and advance his cancer drug development fundamental research, and help more people suffering from cancer globally. ABio was established at the same time and is currently continuing its research in collaboration with GSP,” said Mr Yoshikawa Makoto, the Chairman and Chief Executive Officer of the Group.


Waiting for permission
Allow microphone access to enable voice search

Try again.